SWShenglan Wang

Shenglan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shenglan Wang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Moxibustion improved the effect of fecal microbiota transplantation donor to dextran sulfate sodium‐induced colitis in mice

    by Xinting Wang, Jihong Wu, Rui Huang, Shenglan Wang

    Fecal microbiota transplantation (FMT) is beneficial for several gastrointestinal diseases because it alters the intestinal microbiota of recipients. The efficacy of FMT is related to the microbial structure and composition of the donor. Mild moxibustion is a non‐invasive and safe traditional Chinese therapy that can regulate the gut microbiota. In this study, we investigated whether moxibustion improved the efficacy of FMT in donors using a dextran sulfate sodium (DSS)‐induced colitis mouse model. Normal mice were treated with mild moxibustion at acupoints ST25 and ST36 for 7 days. DSS (2%) was administered for 7 days to induce colitis. FMT was performed on Day 8 and lasted for 7 days. The effect of FMT on mice with DSS was observed on Day 21. Using hematoxylin and eosin staining and immunofluorescence, we analyzed the pathology and cell proliferation after FMT in DSS mice. In addition, using 16 S rDNA sequencing analysis, we investigated the gut microbiota of mice. The results indicated that moxibustion altered the colonic microbial community and increased the relative abundance of specific bacteria without changes in morphology and physiological function in normal mice. FMT using donors with moxibustion reduced body weight loss, inflammation, abnormal microbial community structure, and the relative abundance of some bacteria. These results provide potential strategies for the safe and targeted improvement of FMT donors.


  • Open Access

    Roles of AMPK and Its Downstream Signals in Pain Regulation

    by Shenglan Wang, Yi Dai

    Pain is an unpleasant sensory and emotional state that decreases quality of life. A metabolic sensor, adenosine monophosphate-activated protein kinase (AMPK), which is ubiquitously expressed in mammalian cells, has recently attracted interest as a new target of pain research. Abnormal AMPK expression and function in the peripheral and central nervous systems are associated with various types of pain. AMPK and its downstream kinases participate in the regulation of neuron excitability, neuroinflammation and axonal and myelin regeneration. Numerous AMPK activators have reduced pain behavior in animal models. The current understanding of pain has been deepened by AMPK research, but certain issues, such as the interactions of AMPK at each step of pain regulation, await further investigation. This review examines the roles of AMPK and its downstream kinases in neurons and non-neuronal cells, as well as their contribution to pain regulation.


  • Open Access

    Atractylodin Produces Antinociceptive Effect through a Long-Lasting TRPA1 Channel Activation

    by Hirosato Kanda, Yanjing Yang, Shaoqi Duan, Yoko Kogure, Shenglan Wang, Emiko Iwaoka, Miku Ishikawa, Saki Takeda, Hidemi Sonoda, Kyoka Mizuta, et al.

    Atractylodin (ATR) is a bioactive component found in dried rhizomes of Atractylodes lancea (AL) De Candolle. Although AL has accumulated empirical evidence for the treatment of pain, the molecular mechanism underlying the anti-pain effect of ATR remains unclear. In this study, we found that ATR increases transient receptor potential ankyrin-1 (TRPA1) single-channel activity in hTRPA1 expressing HEK293 cells. A bath application of ATR produced a long-lasting calcium response, and the response was completely diminished in the dorsal root ganglion neurons of TRPA1 knockout mice. Intraplantar injection of ATR evoked moderate and prolonged nociceptive behavior compared to the injection of allyl isothiocyanate (AITC). Systemic application of ATR inhibited AITC-induced nociceptive responses in a dose-dependent manner. Co-application of ATR and QX-314 increased the noxious heat threshold compared with AITC in vivo. Collectively, we concluded that ATR is a unique agonist of TRPA1 channels, which produces long-lasting channel activation. Our results indicated ATR-mediated anti-nociceptive effect through the desensitization of TRPA1-expressing nociceptors.


  • The ubiquitin E3 ligase Nedd4‐2 relieves mechanical allodynia through the ubiquitination of TRPA1 channel in db/db mice

    by Shenglan Wang, Simin Qi, Yoko Kogure, Hirosato Kanda, Lin Tian, Satoshi Yamamoto, Koichi Noguchi, Yi Dai

    Neural precursor cell‐expressed developmentally downregulated protein 4‐2 (Nedd4‐2) is a member of the E3 ubiquitin ligase family that is highly expressed in sensory neurons and involved in pain modulation via downregulation of ion channels in excitable membranes. Ubiquitination involving Nedd4‐2 is regulated by adenosine monophosphate‐activated protein kinase (AMPK), which is impaired in the dorsal root ganglion (DRG) neurons of db/db mice. AMPK negatively regulates the expression of transient receptor potential ankyrin 1 (TRPA1), a recognised pain sensor expressed on the membrane of DRG neurons, consequently relieving mechanical allodynia in db/db mice. Herein, we studied the involvement of Nedd4‐2 in painful diabetic neuropathy and observed that Nedd4‐2 negatively regulated diabetic mechanical allodynia. Nedd4‐2 was co‐expressed with TRPA1 in mouse DRG neurons. Nedd4‐2 was involved in TRPA1 ubiquitination, this ubiquitination, as well as Nedd4‐2–TRPA1 interaction, was decreased in db/db mice. Moreover, Nedd4‐2 levels were decreased in db/db mice, while an abnormal intracellular distribution was observed in short‐term high glucose‐cultured DRG neurons. AMPK activators not only restored Nedd4‐2 distribution but also increased Nedd4‐2 expression. These findings demonstrate that Nedd4‐2 is a potent regulator of TRPA1, and that the abnormal expression of Nedd4‐2 in DRG neurons contributes to diabetic neuropathic pain.


  • Open Access

    Correction: Cui, H., et al. BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation. Int. J. Mol. Sci. 2019, 20, 4062

    by Herong Cui, Wenbo Guo, Beibei Zhang, Guoping Li, Tong Li, Yanyan Yuan, Na Zhang, Yuwei Yang, Wuwen Feng, Fuhao Chu, et al.

    The authors wish to make the following corrections to this paper


  • Open Access

    BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation

    by Herong Cui, Wenbo Guo, Beibei Zhang, Guoping Li, Tong Li, Yanyan Yuan, Na Zhang, Yuwei Yang, Wuwen Feng, Fuhao Chu, et al.

    There is a need for an efficient and low-cost leading compound discovery mode. However, drug development remains slow, expensive, and risky. Here, this manuscript proposes a leading compound discovery strategy based on a combination of traditional Chinese medicine (TCM) formulae and pharmacochemistry, using a ligustrazine–betulinic acid derivative (BA-12) in the treatment of angiogenesis as an example. Blocking angiogenesis to inhibit the growth and metastasis of solid tumors is currently one recognized therapy for cancer in the clinic. Firstly, based on a traditional Prunella vulgaris plaster, BA-12 was synthesized according to our previous study, as it exhibited better antitumor activities than other derivatives on human bladder carcinoma cells (T24); it was then uploaded for target prediction. Secondly, the efficacy and biotoxicity of BA-12 on angiogenesis were evaluated using human umbilical vein endothelial cells (HUVECs), a quail chick chorioallantoic membrane, and Caenorhabditis elegans. According to the prediction results, the main mechanisms of BA-12 were metabolic pathways. Thus, multiple metabolomics approaches were applied to reveal the mechanisms of BA-12. Finally, the predictive mechanisms of BA-12 on glutathione metabolism and glycerophospholipid metabolism activation were validated using targeted metabolomics and pharmacological assays. This strategy may provide a reference for highly efficient drug discovery, with the aim of sharing TCM wisdom for unmet clinical needs.